Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Hyperaldosteronism × Observation × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 19 Prostatic Neoplasms 18 Carcinoma, Non-Small-Cell Lung 16 Neoplasms 15 Endometrial Neoplasms 13 Colorectal Neoplasms 12 Stomach Neoplasms 11 Lung Neoplasms 11 Pancreatic Neoplasms 9 Carcinoma, Hepatocellular 7 Oropharyngeal Neoplasms 6 Multiple Myeloma 6 Lymphoma, Large B-Cell, Diffuse 6 Leukemia, Myeloid, Acute 6 Esophageal Neoplasms 6 Colonic Neoplasms 6 Sarcoma 5 Neoplasm Metastasis 5 Mouth Neoplasms 5 Melanoma 5 Uterine Cervical Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Recurrence 4 Head and Neck Neoplasms 4 Colorectal Neoplasms, Hereditary Nonpolyposis 4 Brain Neoplasms 4 Anus Neoplasms 4 Urinary Bladder Neoplasms 3 Rectal Neoplasms 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3

Interventions

Radiofrequency Ablation 2 ziprasidone 1 Zolpidem 1 Warfarin 1 Vecuronium Bromide 1 Vancomycin 1 Tranexamic Acid 1 Tobramycin 1 Staining and Labeling 1 Spironolactone 1 Sevelamer 1 Rocuronium 1 Prednisone 1 Piperacillin, Tazobactam Drug Combination 1 Pentobarbital 1 Oxycodone 1 Observation 1 Nifedipine 1 Nafcillin 1 Molindone 1 Methylprednisolone 1 Lurasidone Hydrochloride 1 Labetalol 1 Haloperidol 1 Fosfomycin 1 Dexamethasone 1 Clozapine 1 Ciprofloxacin 1 Cidofovir 1 Cefepime 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07272187 2025-12-09

EURAGIL

Herlev Hospital

Hyperaldosteronism, Insulinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡